Poxel Reports Third Quarter 2025 Financial Results

Poxel SA reported its revenue for the third quarter of 2025, highlighting ongoing growth in TWYMEEG® sales in Japan. The sales increased by 5% from the previous quarter and 40% compared to the same quarter last year. Sumitomo Pharma's gross sales for TWYMEEG® reached JPY 5 billion for the first half of 2025, signaling a projected 47% increase for the full fiscal year.

Poxel generated EUR 1,039 thousand in revenue for the third quarter, accumulating to EUR 3,129 thousand over nine months, a 55% rise from 2024. Despite financial challenges, CEO Nicolas Trouche remains optimistic, citing TWYMEEG®'s growth potential.

Projected milestones include achieving JPY 10 billion in net sales, which would trigger royalties and a milestone payment. However, cash flows will be used to repay bonds, and future double-digit royalties are anticipated, dependent on meeting contractual thresholds.